Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide and SBRT for Oligorecurrent Prostate Cancer
NCT04641078Phase 2Recruiting
- Sponsor
- Ghent University Hospital
- Start
- Feb 2021
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Ghent University Hospital. Started Feb 2021; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04641078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641078.